Ind-Swift Laboratories Ltd
INDSWFTLABInd-Swift Laboratories Ltd's price has outrun its earnings. +304.6% in a year against EPS −88.0% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only −36% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (33 weeks in) while the P/E sits at the 100th percentile of its own 8-year range. Underneath, the last four quarters read improving — profit +177.8% year on year, and −36% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Ind-Swift Laboratories Ltd trades at ₹404, in a confirmed uptrend and 33 weeks into that stage. That is +89.9% against its own 200-day average. It sits at 100% of a 52-week range of ₹90 to ₹404. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 24 straight weeks.
Today the stock is in a confirmed uptrend — week 33 of stage 2, confirmed. At ₹404 it trades +89.9% versus its 200-day average and sits at 100% of its 52-week range (₹90–₹404).
Against the market, two honest reads. Cumulative: over the last 10.6 years the stock moved +1,026% while the NIFTY 500 moved +268% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 24 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Ind-Swift Laboratories Ltd trades at 54.5× P/E, about the priciest it has ever traded. Its long-run median P/E is 16.3×, measured across 8.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 54.5× is about the priciest it has ever traded, against a long-run median of 16.3× measured over 8.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −88.0% against a +304.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +44.7%/yr price move, ~+32.3%/yr came from earnings growth and ~+12.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Ind-Swift Laboratories Ltd was paying for profit growth of about 22.9% a year. Today the market pays 54.5× P/E, the 100th percentile of its own 8-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is the whole of what a buyer is backing.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 28 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Ind-Swift Laboratories Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −74.3% latest against +1039.5% at its 12-quarter best), ROCE holding at 5.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +13.1% | −18.7% | −6.1% | −0.1% |
| Profit | −82.8% | −3.6% | — | — |
| EPS | −88.0% | −14.9% | — | — |
| Share price | +304.6% | +67.8% | +44.7% | +26.8% |
4-Factor Sector Score
54.5/100 — rank 13 of 34 in Pharma Formulations · 87% evidence confidence
Ind-Swift Laboratories Ltd scores 54.5 out of 100 against the 34 companies it is compared with in Pharma Formulations, ranking 13. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.1 + 4.9 + 7.5 + 20 = 54.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Ind-Swift Laboratories Ltd reported ₹191 Cr of revenue in the Jun 26 quarter, +24.8% year on year. That is the 5th straight quarter of year-on-year growth. Over 10 years it has compounded at −0.1% a year. The last full year, FY26, came in at ₹649 Cr. The last four reported quarters add to ₹665 Cr.
FY26 revenue came in at ₹649 Cr (+13.1% on the year), capping 10 years at −0.1% compound. The latest quarter (Jun 26) printed ₹191 Cr, +24.8% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +310.0% growth against the decade's −0.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +53.9% over the last 4 quarters against −23.6%/yr over the last 8 — accelerating; TTM profit −74.3% vs −67.4%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Ind-Swift Laboratories Ltd's operating margin is 17.0% in the Jun 26 quarter, +14.6 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −1.2% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 17.0%, +14.6 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −1.2%–21.0%.
Why the margin moved: operating margin went +15.1 pp year on year while gross margin went +7.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Ind-Swift Laboratories Ltd earned ₹25.0 Cr of net profit in the Jun 26 quarter, +177.8% year on year. Full-year FY26 profit was ₹43.0 Cr. That is 13.1% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹25.0 Cr, +177.8% year on year. On the full year, FY26 printed ₹43.0 Cr (−82.8%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −36% of Ind-Swift Laboratories Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−68.0 Cr of operating cash against ₹43.0 Cr of profit. After ₹74.0 Cr of capital spending, ₹−142 Cr was left as free cash.
FY26: operating cash of ₹−68.0 Cr against reported profit of ₹43.0 Cr, leaving free cash of ₹−142 Cr after ₹74.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −36% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −36%: the cash cycle tightened 253 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Ind-Swift Laboratories Ltd's cash conversion cycle runs 114 days in FY26, down from 367 days in FY21. Capital spending ran ₹−171 Cr over the last 3 years. At FY26 sales of ₹649 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹203 Cr sits inside the business at any moment.
FY26: debtors at 112 days, inventory at 187 days — roughly 6.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 114 days, tighter than FY21's 367.
The full loop: cash goes out to suppliers and production on day 0; stock waits 187 days to sell; customers pay about 112 days after that; and suppliers themselves are paid at 185 days — netting out to the 114-day cycle.
In money terms: at FY26 sales of ₹649 Cr, each day of the cycle holds about ₹1.8 Cr — so the 114-day loop keeps roughly ₹203 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−171 Cr over the last 3 fiscal years against ₹108 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹12.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Ind-Swift Laboratories Ltd earns a ROCE of 5% in FY26. That is up from a trough of 0% in FY14. Return on invested capital clears the cost of that capital by −8.8 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.6% net margin on 0.39× asset turns.
FY26 ROCE is 5%, recovered from a FY14 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.6% net margin × 0.39× asset turns × 1.21× balance-sheet leverage ≈ 3.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 3.2% − 12.0% = a −8.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Ind-Swift Laboratories Ltd carries total debt of ₹21.0 Cr against shareholder equity of ₹1,384 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 1.59 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹21.0 Cr against shareholder equity of ₹1,384 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 1.59 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 10.4 points of Ind-Swift Laboratories Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 10.9% of the company. Promoters moved +0.9 points over the same window, to 42.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +10.4 points over 8 quarters to 10.9%; Promoters: +0.9 points over 8 quarters to 42.9%; Domestic institutions: −0.8 points over 8 quarters to 0.1%.
Why the register moved: foreign institutions drove it (+10.4 points), alongside promoters (+0.9 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Ind-Swift Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 72.1/100Favorable setup82% evidence | LEADER | 30.3/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 18.0/25 ROCE 24.1% · OPM 25% 76% evidence | 6.8/20 P/E 46.7× · PEG — 50% evidence | 17.0/20 RS sector 45% · RS bench 105.2% · 1Y 283.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.3 + 18 + 6.8 + 17 = 72.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 67.1/100Favorable setup100% evidence | BREAKING OUT | 29.9/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.6/25 ROCE 39.8% · OPM 20% 100% evidence | 14.0/20 P/E 21× · PEG 1.43 100% evidence | 4.6/20 RS sector -25.4% · RS bench 13.8% · 1Y 14.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.9 + 18.6 + 14 + 4.6 = 67.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -25.4% and the one-year return is 14.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Gland Pharma LtdGLAND | 65.0/100Favorable setup100% evidence | LEADER | 26.6/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.8/25 ROCE 15.1% · OPM 27% 100% evidence | 11.7/20 P/E 42× · PEG 1.45 100% evidence | 12.9/20 RS sector -3.5% · RS bench 44.2% · 1Y 44.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 13.8 + 11.7 + 12.9 = 65 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Accent Microcell LtdACCENTMIC | 64.8/100Mixed-positive evidence63% evidence | LEADER | 17.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 19.1/25 ROCE 24.9% · OPM 16% 95% evidence | 10.2/20 P/E 37× · PEG — 50% evidence | 18.4/20 RS sector 12.6% · RS bench 65.7% · 1Y 151.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 19.1 + 10.2 + 18.4 = 64.8 · Decision use: Price leads the evidence: RS versus the benchmark is 65.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Senores Pharmaceuticals LtdSENORES | 63.7/100Mixed-positive evidence75% evidence | LEADER | 31.7/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 14.8/25 ROCE 15.1% · OPM 30% 76% evidence | 9.6/20 P/E 49.2× · PEG — 15% evidence | 7.6/20 RS sector -6.3% · RS bench 38% · 1Y 90.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.7 + 14.8 + 9.6 + 7.6 = 63.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Corona Remedies LtdCORONA | 63.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 20.6/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.7/25 ROCE 33.3% · OPM 22% 100% evidence | 12.3/20 P/E 61× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 20.6 + 20.7 + 12.3 + 10 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Bliss GVS Pharma LtdBLISSGVS | 63.2/100Mixed-positive evidence82% evidence | LEADER | 28.1/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 15.0/25 ROCE 16.9% · OPM 27% 76% evidence | 6.3/20 P/E 57.5× · PEG — 50% evidence | 13.8/20 RS sector 63.8% · RS bench 128.5% · 1Y 368.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 15 + 6.3 + 13.8 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ipca Laboratories LtdIPCALAB | 61.9/100Mixed-positive evidence82% evidence | LEADER | 24.9/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.9/25 ROCE 17% · OPM 24% 76% evidence | 12.4/20 P/E 35.5× · PEG — 50% evidence | 8.7/20 RS sector -15.4% · RS bench 28% · 1Y 36.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 15.9 + 12.4 + 8.7 = 61.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Emcure Pharmaceuticals LtdEMCURE | 59.3/100Mixed-positive evidence75% evidence | LEADER | 25.6/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.1/25 ROCE 24% · OPM 21% 76% evidence | 10.5/20 P/E 35.9× · PEG — 15% evidence | 5.1/20 RS sector -18.5% · RS bench 23.1% · 1Y 45.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 18.1 + 10.5 + 5.1 = 59.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.5% and the one-year return is 45.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Granules India LtdGRANULES | 59.1/100Mixed-positive evidence100% evidence | LEADER | 26.8/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.3/25 ROCE 15.5% · OPM 23% 100% evidence | 10.0/20 P/E 35.9× · PEG 1.27 100% evidence | 7.0/20 RS sector -13.2% · RS bench 29.9% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 15.3 + 10 + 7 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rubicon Research LtdRUBICON | 56.9/100Mixed-positive evidence73% evidence | BREAKING OUT | 22.6/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 28.4% · OPM 24% 100% evidence | 6.1/20 P/E 94× · PEG 2.35 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 170.9%12 of 12 weeks ahead 0% evidence |
| Exact sum: 22.6 + 18.2 + 6.1 + 10 = 56.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Marksans Pharma LtdMARKSANS | 56.8/100Mixed-positive evidence87% evidence | BREAKING OUT | 24.9/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 16.2/25 ROCE 18.8% · OPM 25% 100% evidence | 6.8/20 P/E 29.4× · PEG 2.85 65% evidence | 8.9/20 RS sector -20.8% · RS bench 59.1% · 1Y 88.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.9 + 16.2 + 6.8 + 8.9 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Ind-Swift Laboratories Ltdthis pageINDSWFTLAB | 54.5/100Mixed-positive evidence87% evidence | LEADER | 22.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence | 4.9/25 ROCE 4.9% · OPM 17% 95% evidence | 7.5/20 P/E 54.5× · PEG — 50% evidence | 20.0/20 RS sector 73.1% · RS bench 145.3% · 1Y 288.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 4.9 + 7.5 + 20 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Caplin Point Laboratories LtdCAPLIPOINT | 54.3/100Mixed-positive evidence100% evidence | LEADER | 16.2/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 18.0/25 ROCE 24.2% · OPM 35% 100% evidence | 11.0/20 P/E 32.4× · PEG 1.52 100% evidence | 9.1/20 RS sector -6.9% · RS bench 39.9% · 1Y 21%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 18 + 11 + 9.1 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Ajanta Pharma LtdAJANTPHARM | 51.8/100Mixed-positive evidence100% evidence | LEADER | 19.4/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 20.1/25 ROCE 34.5% · OPM 26% 100% evidence | 6.9/20 P/E 39× · PEG 2.31 100% evidence | 5.4/20 RS sector -19.2% · RS bench 22.3% · 1Y 39.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 20.1 + 6.9 + 5.4 = 51.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Fredun Pharmaceuticals Ltd539730 | 51.6/100Thin evidence · provisional50% evidence | 16.8/35 Revenue — · PAT — · OPM change 0 pp 24% evidence | 14.8/25 ROCE 21.3% · OPM 14% 76% evidence | 9.1/20 P/E 58.4× · PEG — 15% evidence | 10.9/20 RS sector -29% · RS bench 133.6% · 1Y 26%0 of 6 weeks ahead to 2026-08-16 100% evidence | |
| Exact sum: 16.8 + 14.8 + 9.1 + 10.9 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17RPG Life Sciences LtdRPGLIFE | 51.2/100Mixed-positive evidence93% evidence | LEADER | 9.4/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.6/25 ROCE 25.7% · OPM 22% 100% evidence | 11.6/20 P/E 41.8× · PEG 1.43 65% evidence | 12.6/20 RS sector -11.3% · RS bench 34.8% · 1Y 25%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 17.6 + 11.6 + 12.6 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Strides Pharma Science LtdSTAR | 49.9/100Mixed-negative evidence75% evidence | TURNING | 19.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.2/25 ROCE 18.3% · OPM 18% 76% evidence | 11.5/20 P/E 18.8× · PEG — 15% evidence | 6.0/20 RS sector -18.6% · RS bench 23.7% · 1Y 36%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 13.2 + 11.5 + 6 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Akums Drugs & Pharmaceuticals LtdAKUMS | 49.5/100Mixed-negative evidence75% evidence | LEADER | 11.9/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.7/25 ROCE 14.9% · OPM 15% 76% evidence | 10.1/20 P/E 41.6× · PEG — 15% evidence | 16.8/20 RS sector 3.7% · RS bench 54.1% · 1Y 72%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 10.7 + 10.1 + 16.8 = 49.5 · Decision use: Price leads the evidence: RS versus the benchmark is 54.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Wockhardt LtdWOCKPHARMA | 49.4/100Mixed-negative evidence74% evidence | TURNING | 24.0/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.4/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 89.3× · PEG — 15% evidence | 11.2/20 RS sector -2% · RS bench 46.5% · 1Y 50.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 5.4 + 8.8 + 11.2 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Zydus Lifesciences LtdZYDUSLIFE | 48.9/100Mixed-negative evidence100% evidence | LEADER | 10.5/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.9/25 ROCE 21.1% · OPM 24% 100% evidence | 15.6/20 P/E 24.8× · PEG 1.23 100% evidence | 5.9/20 RS sector -18.8% · RS bench 23.4% · 1Y 16.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 16.9 + 15.6 + 5.9 = 48.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22Suven Life Sciences LtdSUVEN | 47.8/100Mixed-negative evidence67% evidence | LEADER | 19.6/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.3/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.9/20 RS sector 4.2% · RS bench 52% · 1Y 49.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 2.3 + 10 + 15.9 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Kilitch Drugs (India) LtdKILITCH | 47.1/100Mixed-negative evidence87% evidence | TURNING | 11.5/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.4/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.5/20 P/E 25.1× · PEG — 50% evidence | 11.7/20 RS sector -13.3% · RS bench 33.1% · 1Y 24.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 9.4 + 14.5 + 11.7 = 47.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 46.9/100Mixed-negative evidence87% evidence | LEADER | 12.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 16.8/25 ROCE 22.7% · OPM 21% 95% evidence | 11.7/20 P/E 33.9× · PEG — 50% evidence | 5.7/20 RS sector -21.3% · RS bench 20% · 1Y -0.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 16.8 + 11.7 + 5.7 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 44.3/100Mixed-negative evidence96% evidence | 9.3/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.9/25 ROCE 25.4% · OPM 22% 100% evidence | 4.3/20 P/E 53.8× · PEG 2.34 100% evidence | 9.8/20 RS sector -8.2% · RS bench 23.5% · 1Y 40.5%2 of 2 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 9.3 + 20.9 + 4.3 + 9.8 = 44.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Gufic BioSciences LtdGUFICBIO | 41.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.7/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 10.1/25 ROCE 12.3% · OPM 18% 100% evidence | 3.6/20 P/E 56.9× · PEG 4.78 100% evidence | 7.3/20 RS sector -21.1% · RS bench 26.1% · 1Y 14.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 10.1 + 3.6 + 7.3 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Alembic Pharmaceuticals LtdAPLLTD | 41.4/100Mixed-negative evidence94% evidence | BREAKING OUT | 14.1/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.8/25 ROCE 12.6% · OPM 15% 100% evidence | 13.2/20 P/E 22.5× · PEG 1.74 100% evidence | 5.3/20 RS sector -26.6% · RS bench 9.7% · 1Y -9.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.1 + 8.8 + 13.2 + 5.3 = 41.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 28Aurobindo Pharma LtdAUROPHARMA | 39.7/100Mixed-negative evidence100% evidence | LEADER | 14.6/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.7/25 ROCE 12.9% · OPM 21% 100% evidence | 5.9/20 P/E 25.8× · PEG 2.67 100% evidence | 6.5/20 RS sector -14.7% · RS bench 28.4% · 1Y 53%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 12.7 + 5.9 + 6.5 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Bafna Pharmaceuticals LtdBAFNAPH | 39.2/100Mixed-negative evidence60% evidence | BREAKING OUT | 11.1/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.6/20 P/E 110× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 107.9% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 11.1 + 7.3 + 8.6 + 12.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.9/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.0/20 RS sector -34.4% · RS bench 12.5% · 1Y -15.7%8 of 11 weeks ahead 70% evidence |
| Exact sum: 18.9 + 4.3 + 10 + 5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Bharat Parenterals LtdBPLPHARMA | 35.7/100Thin evidence · provisional58% evidence | 11.6/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.0/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.1/20 RS sector -13.5% · RS bench 54.8% · 1Y 44.1%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 11.6 + 4 + 10 + 10.1 = 35.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Torrent Pharmaceuticals LtdTORNTPHARM | 35.5/100Mixed-negative evidence100% evidence | LEADER | 15.3/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 15.2% · OPM 34% 100% evidence | 1.0/20 P/E 85× · PEG 5.11 100% evidence | 4.3/20 RS sector -21.1% · RS bench 19.6% · 1Y 37.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 14.9 + 1 + 4.3 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Zim Laboratories LtdZIMLAB | 34.5/100Adverse evidence79% evidence | LEADER | 8.7/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.2/25 ROCE 4.8% · OPM 2.6% 95% evidence | 6.3/20 P/E 194× · PEG — 50% evidence | 13.3/20 RS sector 6% · RS bench 56.4% · 1Y 83%11 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 6.2 + 6.3 + 13.3 = 34.5 · Decision use: Price leads the evidence: RS versus the benchmark is 56.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Jubilant Pharmova LtdJUBLPHARMA | 33.7/100Adverse evidence93% evidence | TURNING | 8.7/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 5.8/25 ROCE 9% · OPM 11% 100% evidence | 13.4/20 P/E 43.3× · PEG 1.17 65% evidence | 5.8/20 RS sector -27.9% · RS bench 11.8% · 1Y -2.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 5.8 + 13.4 + 5.8 = 33.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Ind-Swift Laboratories Ltd's share price today?
Ind-Swift Laboratories Ltd trades at ₹404, +304.6% over the past year. The company is valued at ₹3,551 Cr. The stock sits at the very top of its 52-week range (₹90–₹404), +89.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 33 weeks in. — as of 28 September 2026.
What were Ind-Swift Laboratories Ltd's latest quarterly results?
Ind-Swift Laboratories Ltd reported revenue of ₹191 Cr and net profit of ₹25.0 Cr for the Jun 26 quarter. Revenue rose 24.8% and profit rose 177.8% year on year. Earnings per share were ₹2.84. The operating margin was 17.0%, 14.6 pp higher than a year earlier. — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's revenue?
Ind-Swift Laboratories Ltd reported revenue of ₹191 Cr in the Jun 26 quarter, +24.8% year on year. For the full FY26 fiscal year, revenue was ₹649 Cr (+13.1%). Over the last 10 years revenue compounded at −0.1% a year. — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's profit?
Ind-Swift Laboratories Ltd earned ₹25.0 Cr of net profit in the Jun 26 quarter, +177.8% year on year. Full-year FY26 profit was ₹43.0 Cr. The operating margin ran 17.0% in the latest quarter. — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's market cap?
Ind-Swift Laboratories Ltd's market capitalisation is ₹3,551 Cr at a share price of ₹404. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's P/E ratio?
Ind-Swift Laboratories Ltd trades at a P/E of 54.5×, at the most expensive it has been in 8 years, against a long-run median of 16.3×. This is a comparison with the stock's own history, not a value call — as of 28 September 2026.
Does Ind-Swift Laboratories Ltd pay a dividend?
No — Ind-Swift Laboratories Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd overvalued?
On its own history, Ind-Swift Laboratories Ltd looks expensive: its P/E of 54.5× sits at the most expensive it has been in 8 years (long-run median 16.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd growing?
Yes — Ind-Swift Laboratories Ltd is growing: latest-quarter revenue +24.8% year on year, profit +177.8%, and the margin +14.6 pp at 17.0%. The earnings engine currently reads: improving — as of 28 September 2026.
How is Ind-Swift Laboratories Ltd performing?
Ind-Swift Laboratories Ltd is in a confirmed uptrend, 33 weeks in. Its latest quarter's revenue rose 24.8% and profit rose 177.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 24 weeks. This describes what the data did, not a rating. — as of 28 September 2026.
What stage is Ind-Swift Laboratories Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −74.3% latest against +1039.5% at its 12-quarter best), ROCE holding at 5.0%. The read comes from the last 12 quarters of growth (revenue growth +53.9% latest, profit growth −74.3% latest, eps growth −81.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 33 of stage 2), trading +89.9% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd beating the market?
On recent form, yes — Ind-Swift Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 24 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.6 years the stock moved +1,026% against the NIFTY 500's +268% — ahead of the index over the full window. — as of 28 September 2026.
Will Ind-Swift Laboratories Ltd's share price go up?
This page publishes no price forecast for Ind-Swift Laboratories Ltd. What it measures instead: the share price is ₹404, the price is in a confirmed uptrend 33 weeks in. Its P/E of 54.5× sits at the 100th percentile of its own 8-year range. — as of 28 September 2026.
Who owns Ind-Swift Laboratories Ltd?
Promoters hold 42.9% of Ind-Swift Laboratories Ltd, foreign institutions 10.9%, domestic institutions 0.1% and the public 46.0% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 10.4 points over 8 quarters. — as of 28 September 2026.
Does Ind-Swift Laboratories Ltd have too much debt?
No — Ind-Swift Laboratories Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 47×. FY26 borrowings were ₹18.0 Cr against equity of ₹1,384 Cr. The returns on this page are earned, not borrowed — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's capex?
Ind-Swift Laboratories Ltd spent ₹−171 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹74.0 Cr, with ₹12.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 28 September 2026.
What is Ind-Swift Laboratories Ltd's cash flow?
Ind-Swift Laboratories Ltd consumed ₹68.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−142 Cr). Operating cash was negative while the company reported a profit of ₹43.0 Cr. Cash-flow resolution for India is annual. — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Ind-Swift Laboratories Ltd consumed cash while reporting profit. In FY26, operating cash was ₹−68.0 Cr against reported profit of ₹43.0 Cr. Cash-flow resolution is annual — as of 28 September 2026.
Where is Ind-Swift Laboratories Ltd in its business cycle?
Ind-Swift Laboratories Ltd's FY26 operating margin was 7.0%, against a 13-year band of −1.2%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 17.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 28 September 2026.
What growth does Ind-Swift Laboratories Ltd's price assume?
At its price on 13 June 2026, Ind-Swift Laboratories Ltd was priced for profit growth of about 22.9% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 28 September 2026.
What could break the Ind-Swift Laboratories Ltd story?
The sharpest disagreement: profits are rising, but only −36% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 28 September 2026.
Is Ind-Swift Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Ind-Swift Laboratories Ltd's price has outrun its earnings. +304.6% in a year against EPS −88.0% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 28 September 2026.
Not SEBI Registered !! Not Investment advice !!